Company
Venus Medtech
Headquarters: Hangzhou, China
Employees: 675
Market Cap
HK$2.48 Billion
HKD as of July 1, 2024
US$317.3 Million
Top Competitors by Market Capitalization
Industry: Medical Devices
| Company | Market Cap (USD) |
|---|---|
| Abbott | $178.02 B |
| Stryker Corporation | $126.48 B |
| Boston Scientific Corporation | $112.32 B |
| Medtronic | $98.95 B |
| Edwards Lifesciences Corporation | $55.63 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Venus Medtech (Hangzhou) Inc. develops and sells transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of cerebral damage during TAVR and other structural heart procedures. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Venus Medtech has the following listings and related stock indices.
Stock: HKEX: 2500 wb_incandescent